CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 447 filers reported holding CRISPR THERAPEUTICS AG in Q2 2024. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $123 | +6.0% | 2,285 | +33.7% | 0.00% | – |
| Q1 2024 | $116 | +8.4% | 1,709 | +0.1% | 0.00% | -100.0% |
| Q4 2023 | $107 | +25.9% | 1,708 | -8.3% | 0.00% | – |
| Q3 2023 | $85 | -21.3% | 1,863 | -2.9% | 0.00% | -100.0% |
| Q2 2023 | $108 | +11.3% | 1,919 | -10.7% | 0.00% | – |
| Q1 2023 | $97 | +10.2% | 2,149 | -1.2% | 0.00% | – |
| Q4 2022 | $88 | -99.6% | 2,176 | +511.2% | 0.00% | – |
| Q3 2022 | $23,000 | 0.0% | 356 | -7.0% | 0.00% | – |
| Q2 2022 | $23,000 | 0.0% | 383 | +3.8% | 0.00% | – |
| Q1 2022 | $23,000 | -11.5% | 369 | +7.6% | 0.00% | – |
| Q4 2021 | $26,000 | -13.3% | 343 | +26.6% | 0.00% | – |
| Q3 2021 | $30,000 | – | 271 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |